ReviewVascular health and risk management2013
Aldosterone receptor antagonists: current perspectives and therapies.
Review in Vascular health and risk management, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Effects of spironolactone in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials.Medicine · 2018Pooled it
- Phase 1 Studies to Define the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone in Healthy Volunteers.Clinical pharmacology in drug development · 2021Trial
- Long-term patiromer adherence and renin-angiotensin aldosterone system inhibitor utilization: A retrospective study.World journal of nephrology · 2026Article
- Evolving Mineralocorticoid Receptor Antagonism: a Narrative Review on Differences between Steroidal MRAs, Non-Steroidal MRAs and Aldosterone Synthase Inhibitors in Cardiorenal Disease.Current heart failure reports · 2026Review
- Potential Significance of Targeting Ferroptosis for Intervention of Diabetic Cardiomyopathy.Journal of diabetes · 2025Review
- Postpartum administration of eplerenone to mitigate vascular dysfunction in mice following a preeclampsia-like pregnancy.Scientific reports · 2025Article
- Finerenone Efficacy in Patients with Chronic Kidney Disease, Type 2 Diabetes, and Anemia in FIDELITY.JACC. Advances · 2025Article
- Therapeutical Approach to Arterial Hypertension - Current State of the Art.Current medicinal chemistry · 2024Review
- Review
- Candidate composite biomarker to inform drug treatments for diabetic kidney disease.Frontiers in medicine · 2023Article
- COVID-19 and Progesterone: Part 1. SARS-CoV-2, Progesterone and its potential clinical use.Endocrine and metabolic science · 2021Article
- Association between chronic kidney disease and the most common corneal ectasia disease (keratoconus): a nationwide cohort study.BMC nephrology · 2021Article
- The Use of Antihypertensive Drugs as Coadjuvant Therapy in Cancer.Frontiers in oncology · 2021Review
- COVID-19 Usurps Host Regulatory Networks.Frontiers in pharmacology · 2020Review
- Involvement of Vanin-1 in Ameliorating Effect of Oxidative Renal Tubular Injury in Dahl-Salt Sensitive Rats.International journal of molecular sciences · 2019Article
- Serum Aldosterone as Predictor of Progression of Coronary Heart Disease in Patients Without Signs of Heart Failure After Acute Myocardial Infarction.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2018Article
- Does growth differentiation factor 11 protect against myocardial ischaemia/reperfusion injury? A hypothesis.The Journal of international medical research · 2017Article
- Mineralocorticoid Receptor Blockade in End-Stage Renal Disease.Current hypertension reports · 2017Review
- Triamterene Enhances the Blood Pressure Lowering Effect of Hydrochlorothiazide in Patients with Hypertension.Journal of general internal medicine · 2016Observational
- The roles of oxidative stress, endoplasmic reticulum stress, and autophagy in aldosterone/mineralocorticoid receptor-induced podocyte injury.Laboratory investigation; a journal of technical methods and pathology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Aldosterone is a downstream effector of angiotensin II in the renin-angiotensin-aldosterone system and binds to the mineralocorticoid receptor. The classical view of aldosterone primarily acting at the level of the kidneys to regulate plasma potassium and intravascular volume status is being supplemented by evidence of new "off-target" effects of aldosterone in other organ systems. The genomic effects of aldosterone are well known, but there is also evidence for non-genomic effects and these recently identified effects of aldosterone have required a revision in the traditional view of aldosterone's role in human health and disease. The aim of this article is to review the biological action of aldosterone and the mineralocorticoid receptor leading to subsequent physiologic and pathophysiologic effects involving the vasculature, central nervous system, heart, and kidneys. Furthermore, we outline current evidence evaluating the use of mineralocorticoid receptor antagonists in the treatment of primary aldosteronism, primary hypertension, resistant hypertension, obstructive sleep apnea, heart failure, and chronic kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.